Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTransense Regulatory News (TRT)

Share Price Information for Transense (TRT)

Share Price is delayed by 15 minutes
Get Live Data
55.50    -0.50 (-0.89%)
Bid:
55.00
Ask:
56.00
Spread: 1.00 (1.818%)
Market Cap: £8.45m
TRT Live PriceLast checked at - London Stock Exchange

Intraday Transense Share Chart

Share Repurchase Programme

27 Sep 2022 07:01

RNS Number : 7146A
Transense Technologies PLC
27 September 2022
 

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which is part of UK law by virtue of the European Union (withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

27 September 2022

 

Transense Technologies plc

("Transense", or "the Company")

 

Share Repurchase Programme

 

Transense Technologies plc (AIM: TRT), the developer of specialist sensor systems, is pleased to announce that it will commence a programme to conduct market purchases of ordinary shares of 10 pence each in the Company ("Ordinary Shares") up to a maximum aggregate purchase price of £650,000 (the "Programme").

 

The Company has entered into an arrangement with Shard Capital Stockbrokers ("Shard") in relation to the Programme where Shard will make the trading decisions concerning the timing of the market purchases of Ordinary Shares independently of and uninfluenced by the Company, with such trading decisions being in accordance with the terms of the Programme. Purchases may continue during any periods during the term of the Programme when the Company itself would be prohibited from dealing by the UK version of the Market Abuse Regulation 596/2014/EU (which is part of UK law by virtue of the European Union (Withdrawal) Act 2018) ("UK MAR"). The Company reserves the right to terminate the Programme if at any time it deems this to be appropriate and would make an announcement in advance of so doing.

 

The Company confirms that it currently has no unpublished inside information.

 

The Programme will commence today, 27 September 2022, and will continue until 30 November 2023 unless terminated earlier.

 

The Programme will be conducted by the Company in accordance with and under the terms of the general authority granted by the Company's shareholders at the Company's Annual General Meeting on 23 November 2021 to purchase up to 1,643,774 Ordinary Shares. This authority will expire at the earlier of the end of the next Annual General Meeting of the Company or 23 February 2023. Purchases under the Programme prior to the Annual General Meeting of the Company to be held on 1 December 2022 will be restricted to an aggregate of £150,000, and the balance of the Programme will continue after the Annual General Meeting subject to renewal of the appropriate authority by the shareholders.

 

Any market purchases will be conducted in compliance with the following restrictions regarding price conditions:

· the minimum price (exclusive of any expenses) at which any Ordinary Share may be purchased shall be its nominal value of 10 pence

· the maximum price (exclusive of any expenses) at which any Ordinary Share may be purchased shall be the higher of: (i) an amount equal to 5 per cent, above the average of the middle market quotations of an Ordinary Share as derived from the London Stock Exchange Daily Official List for the five business days immediately preceding the date of such purchase, and (ii) the higher of the price of the last independent trade and the highest current independent bid on the trading venue where the purchase is carried out.

 

Due to the limited liquidity in the Ordinary Shares, any market purchase of Ordinary Shares pursuant to the Programme on any trading day could represent a significant proportion of the daily trading volume in the Ordinary Shares on AIM and could exceed 25 per cent. of the average daily trading volume. This means that the Company will not benefit from the exemption contained in Article 5(1) of UK MAR.

 

The objective of the Programme is to offset the dilutive impact of share awards to directors and employees.

 

Ordinary Shares acquired as a result of the Programme will be held by the Company in treasury and in accordance with the Companies Act 2006, will not have any voting rights. It is anticipated that any Ordinary Shares held in treasury but surplus to unexercised option requirements from time to time will be cancelled.

 

For further information please visit www.transense.com or contact:

 

Transense Technologies plc

Nigel Rogers (Executive Chairman)

Melvyn Segal (CFO)

Via Walbrook PR

Allenby Capital (Nominated Adviser and Broker)

Jeremy Porter / George Payne (Corporate Finance)

Tony Quirke (Sales & Corporate Broking)

Tel: +44 (0)20 3328 5656

Walbrook PR

Tom Cooper / Nick Rome

Tel: +44 (0)20 7933 8780

Transense@walbrookpr.com

 

Notes to Editors:

Transense is a developer of specialist wireless sensor systems used to enable real-time data gathering and monitoring. Products include the patent protected Surface Acoustic Wave (SAW) sensor technology, used to improve equipment power, performance, reliability and efficiency; iTrack, Transense 's Tyre Pressure Monitoring System, licensed to Bridgestone Corporation, the world's largest tyre producer, under a ten-year deal in June 2020; and a range of intelligent tyre monitoring equipment under the Translogik brand. Target sectors include aerospace, electric motors & drives, industrial machinery and performance automotive. 

The Company's strategy is to maximise shareholder value through the delivery of sustained revenue growth from all three principal technologies - SAW, iTrack and Translogik probes - through leveraging excellence in innovation, know-how in commercialising technologies, industry partnerships and exposure to global growth markets.

Transense is headquartered in Oxfordshire, UK, and was admitted to trading on AIM, a market operated by the London Stock Exchange (AIM: TRT), in 1999.  www.transense.com.

For further information please contact transense@walbrookpr.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFEAARIRFIF
Date   Source Headline
17th Dec 20201:19 pmRNSResult of AGM
17th Dec 20207:00 amRNSAGM Update, new Website & Investor Presentation
9th Dec 20207:00 amRNSEstablishment of SAW Commercial Advisory Panel
23rd Nov 20207:00 amRNSPosting of Annual Report and Notice of AGM
6th Nov 20203:38 pmRNSDirector/PDMR Shareholding
22nd Oct 20208:45 amRNSHolding(s) in Company
20th Oct 202012:09 pmRNSDirector/PDMR Shareholding
20th Oct 20207:00 amRNSFinal results for the year ended 30 June 2020
19th Oct 20207:00 amRNSChange of Nomad and Broker & AIM Rule 17 update
12th Oct 20207:00 amRNSNotice of Results and Investor Presentation
10th Sep 20207:00 amRNSFinal consideration for iTrack transfer
25th Aug 202010:23 amRNSDirector/PDMR Shareholding
24th Aug 20209:27 amRNSHolding(s) in Company (Replacement)
20th Aug 20205:02 pmRNSHolding(s) in Company
8th Jul 20204:16 pmRNSDirector/PDMR Shareholding
7th Jul 20203:38 pmRNSHolding(s) in Company
3rd Jul 202011:30 amRNSHolding(s) in Company
3rd Jul 20207:00 amRNSInvestor Presentation
1st Jul 20206:12 pmRNSHolding(s) in Company
26th Jun 20201:54 pmRNSDirector/PDMR Shareholding
26th Jun 20207:00 amRNSGrant of Options/PDMR Dealing
25th Jun 20204:41 pmRNSDirector/PDMR Shareholding
25th Jun 20202:10 pmRNSDirector/PDMR Shareholding
25th Jun 20207:01 amRNSStrategic Update
25th Jun 20207:00 amRNSBridgestone Granted Worldwide iTrack Licence
12th Jun 202010:40 amRNSUpdate relating to the JCA with Bridgestone
1st Jun 20207:00 amRNSUpdate relating to the JCA with Bridgestone
5th May 20202:39 pmRNSHolding(s) in Company
1st May 20207:00 amRNSUpdate relating to the JCA with Bridgestone
16th Mar 20207:00 amRNSFurther Working Capital Loan Agreement
20th Feb 20207:00 amRNSInterim Results
20th Feb 20207:00 amRNSInterim Results
19th Feb 20207:00 amRNSChanges to Board responsibilities
13th Feb 20207:01 amRNSNotice of Interim Results
13th Feb 20207:00 amRNSExtension to Agreement with Bridgestone
19th Dec 20194:14 pmRNSResult of AGM
19th Dec 20197:00 amRNSAGM Statement
19th Nov 20197:00 amRNSNotice of AGM
15th Nov 20194:53 pmRNSHolding(s) in Company
7th Nov 20191:13 pmRNSHolding(s) in Company
26th Sep 20197:00 amRNSFinal results for the year ended 30 June 2019
14th Aug 20199:09 amRNSHolding(s) in Company
13th Aug 20192:45 pmRNSAwards of Options
13th Aug 20197:00 amRNSJoint Collaboration Agreement with Bridgestone
30th Jul 20197:00 amRNSTrading Update
1st Jul 201912:02 pmRNSHolding(s) in Company
30th Apr 20194:10 pmRNSHolding(s) in Company
29th Apr 20198:52 amRNSHolding(s) in Company
26th Apr 20191:42 pmRNSHolding(s) in Company
4th Apr 201910:31 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.